Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool November 19, 2004 Charly Travers	A New Drug for Lung Cancer Genentech and OSI's launch of Tarceva brings a new choice in the treatment of lung cancer.
The Motley Fool April 26, 2004 Alyce Lomax	Genentech's Lucky Day Genentech and OSI Pharmaceuticals jump in today's trading session after favorable trial results for a cancer drug.
The Motley Fool December 20, 2004 Charly Travers	More Trouble at Big Pharma AstraZeneca's lung cancer drug is not as effective as once hoped.
The Motley Fool June 4, 2008 Brian Lawler	Erbitux's Deceptively Disappointing Results Poorly received lead-drug data batters ImClone shares.
The Motley Fool January 5, 2005 Charly Travers	AstraZeneca's Lead Evaporates Pulling an application for Iressa from the EU makes the drug a has-been.
The Motley Fool May 5, 2005 Charly Travers	OSI's Cancer Blockbuster Tarceva will turn OSI Pharmaceuticals into a leading biotech.
The Motley Fool April 12, 2005 Brian Gorman	Genentech's Cancer Quest The company's achievements in lung cancer further strengthen its reputation as a cancer fighter. Would-be investors are best served by waiting patiently.
BusinessWeek May 9, 2005 Catherine Arnst	Genentech's Lessons For Big Pharma The biotech company focuses on science -- not marketing, acquisitions, or patents.
The Motley Fool December 3, 2004 W.D. Crotty	One Hot Biotech Stock Biomira reports favorable Phase II test results, sending the stock up 146%.
The Motley Fool June 15, 2010 Brian Orelli	Just Enough to Give Investors Hope Hitting a secondary endpoint means all is not lost for Onyx's lung cancer drug.
Bio-IT World October 10, 2003 Kevin Davies	Iressa's Trials and Tribulations The Iressa experience highlights the enormous stakes surrounding breakthrough therapies.
The Motley Fool July 6, 2009 Brian Orelli	Lilly Shows Us How It's Done The company announces that the Food and Drug Administration had expanded the approval of its cancer drug, Alimta, to include maintenance therapy for nonsquamous, non-small cell lung cancer.
The Motley Fool November 21, 2008 Brian Orelli	The Comeback of the Century? AstraZeneca is trying to revive Iressa.
The Motley Fool March 30, 2010 Brian Orelli	Invest in This Space at Your Own Risk Lung cancer is a tough foe for drugmakers.
The Motley Fool July 16, 2007 Brian Lawler	Slight Setback for ImClone ImClone announces a failed cancer study. Investors, take note.
The Motley Fool March 15, 2005 Charly Travers	The Best Company I've Never Owned The history of Genentech's Avastin, which just completed another phase 3 clinical trial showing that Avastin is effective in the treatment of non-small cell lung cancer. The author laments missing the opportunity to invest.
The Motley Fool September 17, 2010 Luke Timmerman	Cell Therapeutics OK'd to Sell Shares to Stay Alive Is the company being straight with shareholders?
Pharmaceutical Executive July 1, 2011 Dickmeyer & Rosenbeck	From Rut to Racetrack Can the pharmaceutical industry deliver on its objective to make cancer a curable, chronic condition?
BusinessWeek August 26, 2010 Tom Randall	Cocktails Are Next For Cancer-Drug Makers Taking a cue from the cocktails of drugs that have made AIDS survivable, drugmakers are pursuing combination therapies against cancer.
BusinessWeek June 21, 2004 Catherine Arnst	Cancer Superdrugs, Costly Side Effects New therapies are extending lives, but the prices could weigh down the nation. Oncologists, pharmaceutical companies, and the government will have to focus on the best way to lower prices for these drugs.
The Motley Fool April 27, 2011 Brian Orelli	Falling Into the Zaltrap Lung cancer out, colon cancer in phase 3 clinical trial for Regeneron Pharmaceuticals' new drug.
The Motley Fool May 28, 2009 Brian Orelli	Make Money, Fight Disease: The ASCO Preview The big cancer meeting is upon us.
BusinessWeek May 23, 2005 Catherine Arnst	If It Works for Breast Cancer... Studies are under way to see if promising strategies used against breast cancer can be used to fight other killers, such as lung, colon, and prostate cancer.
The Motley Fool June 6, 2011 Brian Orelli	Big Pharma Tackles Lung Cancer; Biotech Helping, Too A big underserved market.
The Motley Fool February 25, 2008 Brian Lawler	A Positive Surprise for Genentech Biopharma Genentech's lead drug gets a conditional OK to treat breast cancer.
The Motley Fool January 22, 2010 Brian Orelli	Pfizer's Great Data Won't Do Much The full data from a clinical trial testing Pfizer's Sutent in pancreatic cancer was truly amazing. Unfortunately, it's not going to do very much for the stock or Pfizer's bottom line.
The Motley Fool May 22, 2008 Brian Lawler	All Is Not Lost for AstraZeneca's Iressa AstraZeneca's Iressa gets a little pep back.
The Motley Fool September 13, 2007 Brian Lawler	ImClone Expanding on Erbitux ImClone's turnaround continues with positive results in a cancer study with their lead drug Erbitux.
The Motley Fool March 21, 2011 Brian Orelli	Let's See Some Data, Curis Curis investors seem to have shrugged off the multiple unknowns and embraced the potential for the company's skin cancer drug.
The Motley Fool May 24, 2010 Brian Orelli	ASCO Abstracts -- Pops and Drops! Ever since The American Society of Clinical Oncology began posting abstracts on-line -- and before that when they were sent to attendees -- investors have clamored to get a glimpse at the data. Here's your glimpse.
The Motley Fool July 12, 2010 Ryan McBride	Synta Pharma CEO Trumpets New Top Cancer Drug Synta Pharmaceuticals has been climbing back from one of the Boston area's highest-profile clinical trial failures of 2009.
Bio-IT World June 17, 2004	Minority Report With Iressa, the AstraZeneca drug approved by the FDA last year, there is a small group, maybe 10 to 20 percent of lung cancer patients, who get an almost miraculous response. Mutations may explain patient responses to the drug.
The Motley Fool February 21, 2008 Brian Orelli	Onyx's Double Dose of Trouble Poor clinical trial data and a lack of profits hit the drugmaker hard. Investors, take note.
The Motley Fool November 21, 2008 Brian Orelli	Coughing Is Bad for Amgen's Health Safety concerns halt drug trial, but all is not lost.
Pharmaceutical Executive December 1, 2010 Walter Armstrong	Non-Small-Cell Lung Cancer: Targeting Pathways and Patients Although the most common cancer worldwide, lung cancer remains poorly treated, with the highest mortality rate.
The Motley Fool September 11, 2006 Brian Lawler	More Work on Cancer Drug for Genentech The FDA asks for more data about Avastin, which could be used to treat various cancers. Investors, take note.
The Motley Fool June 17, 2010 Luke Timmerman	Oncothyreon's Cancer Vaccine Back in the Saddle as Merck KGaA Re-Starts Clinical Trials The German-based Merck got clearance from the FDA and local ethics review boards to resume two of three large pivotal trials.
BusinessWeek May 27, 2010 Pettypiece & Gibson	Training the Immune System to Fight Cancer Bristol-Myers' new melanoma drug may be a "game changer."
The Motley Fool November 29, 2011 Brian Orelli	Winners and Losers of Roche's Avastin Woes What the FDA giveth, the FDA can taketh away.
Pharmaceutical Executive December 1, 2010 Walter Armstrong	Cancer: On Target Once More Over the past year or two, a handful of Phase III failures, including megablockbusters like Avastin and Sutent in trials for all kinds of common tumors, indicate that targeted therapy is generally a blunt instrument.
The Motley Fool February 27, 2004 Alyce Lomax	Genentech's Hope For the past two days, Genentech has been an example of what many investors hinge their hopes and dollars on. Yesterday's FDA approval of the company's groundbreaking cancer drug, Avastin, was the reason positive sentiment remained infectious today.
The Motley Fool March 16, 2011 Brian Orelli	Different Name, Same Great Results Incyte and Novartis' ruxolitinib passes another clinical trial.
The Motley Fool December 30, 2009 Brian Orelli	Pfizer Pflubs -- You Expected Otherwise? Bad news, but rather expected.
The Motley Fool February 16, 2010 Brian Orelli	For Blockbuster Cancer Drugs, Approvals Are the Easy Part Don't get too excited. As an investor, you can lower your risk by investing in cancer drug companies after a clinical trial success but before an FDA approval, but you'll also reduce your reward.
The Motley Fool November 8, 2007 Brian Orelli	Investors Prefer Black Onyx Sales of Onyx's only drug, Nexavar, exceeded $100 million in the third quarter, enough for Onyx to show a profit. Investors, take note.
The Motley Fool March 23, 2004 David Nierengarten	Genentech's Star Power How much higher can Genentech go?
The Motley Fool September 7, 2010 Luke Timmerman	Vertex Nails Third Big Trial With Hepatitis C Drug And in the toughest patients to treat, too.
The Motley Fool June 9, 2010 Brian Orelli	ASCO Pops and Drops Themes and company news from the annual meeting of the American Society of Clinical Oncology.
HHMI Bulletin Nov 2010	Fusion genes that drive solid tumors are a new target for cancer therapies The success of Gleevec and related drugs has inspired researchers to step up their hunt for the molecular defects underlying other cancers.
The Motley Fool May 31, 2011 Brian Orelli	5 Biotechs With Upcoming Clinical Trial Results Investors willing to stay in these stocks a little while could see substantial gains well ahead of FDA approvals.